Pancreatic Ductal Carcinoma Market

Market Overview:

The 7 major pancreatic ductal carcinoma markets are expected to exhibit a CAGR of 5.79% during 2024-2034.

The Pancreatic ductal carcinoma market has been comprehensively analyzed in IMARC's new report titled "Pancreatic ductal carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pancreatic ductal carcinoma, also known as pancreatic adenocarcinoma, is a type of cancer that originates in the cells lining the ducts of the pancreas. It is often characterized by the uncontrolled growth and division of these ductal cells, leading to the formation of malignant tumors in the pancreas. Some of the common symptoms of the ailment include abdominal pain or discomfort, jaundice, loss of appetite, fatigue, nausea and vomiting, digestive problems, unexplained weight loss, and new-onset diabetes or changes in blood sugar levels. The diagnosis of Pancreatic ductal carcinoma typically involves a combination of imaging tests, laboratory analyses, and sometimes tissue sampling. Initial diagnostic imaging may include computed tomography (CT) scans, magnetic resonance imaging (MRI), endoscopic ultrasound (EUS), etc., to visualize the pancreas and assess the presence of a tumor. Additionally, blood tests are also conducted to evaluate liver function, pancreatic enzymes, and tumor markers. For confirming the diagnosis and determining the cancer stage, a tissue biopsy is often performed, either through a fine needle aspiration (FNA) or a surgical biopsy.

The increasing cases of chronic pancreatitis that involve ongoing inflammation of the pancreatic tissue, thereby leading to DNA damage and genetic alterations over time, are primarily driving the Pancreatic ductal carcinoma market. In addition to this, the growing prevalence of various associated risk factors, such as genetic predisposition, diabetes, obesity, heavy and prolonged alcohol consumption, advancing age, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies that specifically target certain molecular alterations or pathways involved in cancer growth is further bolstering the market growth. Apart from this, the inflating application of immune checkpoint inhibitors, including pembrolizumab and nivolumab, which harness the body's immune system to recognize and destroy cancer cells, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgeries, since they offer smaller incisions, reduced blood loss, faster recovery times, and potentially fewer complications compared to traditional open surgery, is expected to drive the Pancreatic ductal carcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Pancreatic ductal carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Pancreatic ductal carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Pancreatic ductal carcinoma market in any manner.

Recent Developments:

• In February 2024, Ipsen disclosed that the Food and Drug Administration had given the green light for the initial treatment of metastatic pancreatic adenocarcinoma using irinotecan liposome (sold as Onivyde by Ipsen Biopharmaceuticals, Inc.), combined with oxaliplatin, fluorouracil, and leucovorin.
• In February 2024, BioLineRx Ltd. announced that the randomized CheMo4METPANC Phase 2 combination clinical trial has initiated dosing for its first patient. This trial evaluates the effectiveness of the company's CXCR4 inhibitor Motixafortide, the PD-1 inhibitor Cemiplimab, alongside standard chemotherapies gemcitabine and nab-paclitaxel, compared to the use of gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancer (PDAC) treatment.
• In December 2023, Candel Therapeutics, Inc. received Fast Track Designation from the FDA for their treatment involving Aglatimagene Besadenovec (CAN-2409) in conjunction with valacyclovir, intended for patients suffering from pancreatic ductal adenocarcinoma (PDAC).
• In December 2023, Lisata Therapeutics announced the fulfillment of enrollment for the Phase 2b ASCEND Trial, investigating LSTA1's efficacy in treating metastatic pancreatic ductal adenocarcinoma. Lisata is projecting the disclosure of top-line data from Cohort A, consisting of 95 patients, by the fourth quarter of 2024, and the comprehensive dataset encompassing all 155 participants from the study to be accessible by mid-2025.
• In November 2023, Immunovia reported the successful conclusion of the discovery phase for its upcoming test, signifying a pivotal advancement in its development. This study identified over a dozen proteins present in the bloodstream capable of detecting patients with early-stage pancreatic ductal adenocarcinoma (PDAC) in both stage I and stage II.

Key Highlights:

• The age-adjusted incidence rates for different stages of PDAC saw an upward trend. Early-stage PDAC experienced an increase from 1.1 to 2.8 per 100,000 person-years, while locally advanced PDAC rose from 3.6 to 4.3, and metastatic PDAC increased from 6.4 to 7.7.
• In the United States for the year 2024, the American Cancer Society estimates that pancreatic cancer diagnoses will reach around 66,440 individuals, with approximately 34,530 men and 31,910 women affected. The projections also indicate that approximately 51,750 people will succumb to pancreatic cancer, including about 27,270 men and 24,480 women.
• Pancreatic cancer constitutes 22% of fatalities from gastrointestinal malignancies and 5% of overall cancer-related deaths.
• Pancreatic cancer is most identified in individuals aged 50 and above, with its highest prevalence occurring between the ages of 70 and 80. The occurrence of pancreatic cancer is less frequent among those under the age of 40 and is typically associated with genetic influences.

Drugs:

Onvansertib is an investigational drug being developed by Cardiff Oncology for the treatment of pancreatic ductal carcinoma. It is a highly selective and potent inhibitor of the protein kinase PLK1, which plays a key role in cell division and is often overexpressed in cancer cells. By inhibiting PLK1, onvansertib has the potential to disrupt cancer cell division and growth.

Vobramitamab duocarmazine (MGC-018) is under development for the treatment of solid tumors including pancreatic cancer. It is delivered via intravenous route of administration. The treatment candidate is an antibody-drug combination duocarmycin-based linker payload that targets cells that express the CD276 antigen (B7-H3).

ELI-002 is a potential treatment being developed by Elicio Therapeutics for pancreatic ductal carcinoma. It is designed to activate the immune system's response against cancer cells. This therapeutic agent is based on the company's Amphiphile platform, which aims to deliver antigens directly to immune cells to trigger a stronger and more targeted immune response against tumors.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pancreatic ductal carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pancreatic ductal carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pancreatic ductal carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pancreatic ductal carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the pancreatic ductal carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the pancreatic ductal carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of pancreatic ductal carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pancreatic ductal carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pancreatic ductal carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with pancreatic ductal carcinoma across the seven major markets?
• What is the size of the pancreatic ductal carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pancreatic ductal carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Pancreatic Ductal Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pancreatic ductal carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pancreatic ductal carcinoma market?
• What are the key regulatory events related to the pancreatic ductal carcinoma market?
• What is the structure of clinical trial landscape by status related to the pancreatic ductal carcinoma market?
• What is the structure of clinical trial landscape by phase related to the pancreatic ductal carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the pancreatic ductal carcinoma market?